Thai conglomerate Charoen Pokphand (CP) Group will develop a group of bases in Zhuhai capable of researching and commercializing artificial intelligence and biomedicine, among other technologies.

Product manufacturing and sales will come later.

Based in Bangkok, the world's leading listed agro-industrial and food conglomerate is known as Chia Tai Group in the Chinese mainland. It will implement projects under a partnership agreement with the Zhuhai government signed on Sept 11.

Chairman of CP Pharmaceutical Group, Tse Ping [Photo courtesy cpgroup.cn]

The CP New Materials Research Institute will seek technological breakthroughs in developing safe, energy-saving, environmentally protective, green, and low-carbon new materials. Another research institute for AI & Biomedical innovations will develop synthetic biology technology and related bio-based products. It will also research innovative drugs for cardiovascular and cerebrovascular diseases, as well as precision medical and AI-related technologies and products.

In the meantime, the Research Institute of Cross-border Data Trading & CP Zhuhai Big Data Base will integrate Zhuhai resources and regional advantages into its operations, which should boost local innovation and entrepreneurship.

Other projects include the Biomedical Public Technology R&D & Service Platform, and Biomedical New Materials Production Base.

Tse Ping, senior vice president of CP Group and chairman of CP Pharmaceutical Group, attended the ceremony in the presence of Zhuhai Party Secretary Guo Yongkang and Zhuhai Mayor Yao Yisheng.